Pomalidomide-amino-PEG4-NH2 is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker molecule, connecting a target protein-binding ligand (such as pomalidomide) to an E3 ubiquitin ligase recruiter. This facilitates the degradation of specific disease-causing proteins, making it a valuable tool in treating conditions like multiple myeloma and other cancers. Additionally, its PEG4 spacer enhances solubility and stability, improving the pharmacokinetic properties of the drug conjugate. This compound is also explored in antibody-drug conjugates (ADCs) for selective delivery of therapeutic agents to cancer cells, minimizing off-target effects.